Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: An instrumental variable analysis of the AURA study

Eye (Basingstoke)

Volumn 30, Issue 8, 2016, Pages 1063-1071

  Holz, F G ^a   Tadayoni, R ^b   Beatty, S ^c   Berger, A R ^d   Cereda, M G ^e   Hykin, P ^f   Staurenghi, G ^e   Wittrup Jensen, K ^g   Nilsson, J ^h   Kim, K ⁱ   Sivaprasad, S ^f,j  

^a UNIVERSITY OF BONN   (Germany)

^b HÔPITAL LARIBOISIÈRE   (France)

^c Institute of Eye Surgery   (Ireland)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITY OF MILAN   (Italy)

^f MOORFIELDS EYE HOSPITAL   (United Kingdom)

^g BAYER PHARMA AG   (Germany)

^h MAPI GROUP   (Netherlands)

ⁱ ASTRAZENECA R AND D   (Sweden)

^j KING S COLLEGE HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CANADA; FEMALE; FLUORESCENCE ANGIOGRAPHY; FRANCE; GERMANY; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; IRELAND; ITALY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NETHERLANDS; OBSERVATIONAL STUDY; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; REIMBURSEMENT; RETINA NEOVASCULARIZATION; RETROSPECTIVE STUDY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; TREATMENT DURATION; UNITED KINGDOM; VENEZUELA; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; CONTROLLED STUDY; INTRAVITREAL DRUG ADMINISTRATION; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; OPHTHALMOSCOPY; RANIBIZUMAB; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84982121614     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2016.90     Document Type: Article

References (26)

1. Ablonczy Z, Dahrouj M, Marneros AG. Progressive dysfunction of the retinal pigment epithelium and retina due to increased VEGF-A levels. FASEB J 2014; 28: 2369-2379.
2. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444.
3. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
4. Hariprasad SM, Morse LS, Shapiro H, Wong P, Tuomi L. Fixed monthly versus less frequent ranibizumab dosing and predictors of visual response in exudative age-related macular degeneration. J Ophthalmol 2012; 2012: 690641.
5. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2008; 145: 239-248.
6. Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 2011; 118: 831-839.
7. Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011; 118: 663-671.
8. Busbee BG, Ho AC, Brown DM, Heier JS, Suner IJ, Li Z et al. Twelve-month efficacy and safety of 0. 5 mg or 2. 0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2013; 120: 1046-1056.
9. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012; 119: 1388-1398.
10. Berg K, Pedersen TR, Sandvik L, Bragadottir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 2015; 122: 146-152.
11. Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R et al. Multi-country real-life experience of antivascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 2015; 99: 220-226.
12. Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Hykin P et al. Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. Br J Ophthalmol 2016, e-pub ahead of print 30 March 2016; doi:10. 1136/bjophthalmol-2015-308166.
13. Rakic JM, Leys A, Brié H, Denhaerynck K, Pacheco C, Vancayzeele S et al. Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study. Clin Ophthalmol 2013; 7: 1849-1858.
14. Brookhart MA, Rassen JA, Schneeweiss S. Instrumental variable methods in comparative safety and effectiveness research. Pharmacoepidemiol Drug Saf 2010; 19: 537-554.
15. Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol 2000; 29: 1102.
16. Little RJ, Rubin DB. Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches. Annu Rev Public Health 2000; 21: 121-145.
17. Martens EP, Pestman WR, de BA, Belitser SV, Klungel OH. Instrumental variables: application and limitations. Epidemiology 2006; 17: 260-267.
18. Staiger D, Stock JH. Instrumental variables regression with weak instruments. Econometrica 1997; 65: 557-586.
19. Theil H. Principles of Econometrics. Wiley: New York, 1971.
20. Zohoori N, Savitz DA. Econometric approaches to epidemiologic data: relating endogeneity and unobserved heterogeneity to confounding. Ann Epidemiol 1997; 7: 251-257.
21. Lin WY, Lee CC, Hsu CW, Huang KY, Lyu SR. Patients with knee osteoarthritis undergoing total knee arthroplasty have a lower risk of subsequent severe cardiovascular events: propensity score and instrumental variable analysis. PLoS One 2015; 10: e0127454.
22. Maeda JL, Henke RM, Marder WD, Karaca Z, Friedman BS, Wong HS. Association between the unemployment rate and inpatient cost per discharge by payer in the United States, 2005-2010. BMC Health Serv Res 2014; 14: 378.
23. Scientific Department The Royal College of Ophthalmologists. Age-related macular degeneration: guidelines for management. The Royal College of Ophthalmologists website http://www. rcophth. ac. uk/wpcontent/ uploads/2014/12/2013-SCI-318-RCOphth-AMDGuidelines-Sept-2013-FINAL-2. pdf (accessed 26 April 2016).
24. Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 2014; 98: 1144-1167.
25. Hassenstein A, Spital G, Scholz F, Henschel A, Richard G, Pauleikhoff D. [Optical coherence tomography for macula diagnostics. Review of methods and standardized application concentrating on diagnostic and therapy control of age-related macula degeneration]. Ophthalmologe 2009; 106: 116-126.
26. Burgess S, Thompson SG. Improving bias and coverage in instrumental variable analysis with weak instruments for continuous and binary outcomes. Stat Med 2012; 31: 1582-1600.